Pfizer Ends Study on Potential Lung Cancer Drug ABC News It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug Seattle Times It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug Huffington Post (blog) It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer Ends Study on Potential Lung Cancer Drug PharmaLive (press release) (subscription) It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug The Associated Press It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug Atlanta Journal Constitution It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug Town Hall It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
BC cancer researchers make lymphoma 'breakthrough' Windsor Star In the study, which investigated patient records, the 10-year survival rate in patients with the highest number of the macrophages was 59.6 per cent ...
Pfizer ends study on potential lung cancer drug MiamiHerald.com It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug Bismarck Tribune It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
B.C. cancer researchers make lymphoma 'breakthrough' Canada.com In the study, which investigated patient records, the 10-year survival rate in patients with the highest number of the macrophages was 59.6 per cent ...
Pfizer ends study on potential lung cancer drug CNBC It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug York Daily Record It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
